PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of celldivBioMed CentralBiomed Central Web Sitesearchsubmit a manuscriptregisterthis articleCell DivisionJournal Front Page
 
Cell Div. 2010; 5: 26.
Published online Oct 18, 2010. doi:  10.1186/1747-1028-5-26
PMCID: PMC2976740
JAB1/CSN5: a new player in cell cycle control and cancer
Terry J Shackleford1 and Francois X Claretcorresponding author1
1Department of Systems Biology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
corresponding authorCorresponding author.
Terry J Shackleford: tjjohnso/at/mdanderson.org; Francois X Claret: fxclaret/at/mdanderson.org
Received September 20, 2010; Accepted October 18, 2010.
c-Jun activation domain-binding protein-1 (Jab1) acts as a modulator of intracellular signaling and affects cellular proliferation and apoptosis, through its existence as a monomer or as the fifth component of the constitutive photomorphogenic-9 signalosome (CSN5). Jab1/CSN5 is involved in transcription factor specificity, deneddylation of NEDD8, and nuclear-to-cytoplasmic shuttling of key molecules. Jab1/CSN5 activities positively and negatively affect a number of pathways, including integrin signaling, cell cycle control, and apoptosis. Also, more recent studies have demonstrated the intriguing roles of Jab1/CSN5 in regulating genomic instability and DNA repair. The effects of Jab1/CSN5's multiple protein interactions are generally oncogenic in nature, and overexpression of Jab1/CSN5 in cancer provides evidence that it is involved in the tumorigenic process. In this review, we highlight our current knowledge of Jab1/CSN5 function and the recent discoveries in dissecting the Jab1 signaling pathway. Further, we also discuss the regulation of Jab1/CSN5 in cancers and its potential as a therapeutic target.
Through detailed knowledge of oncogenic signal transduction pathways, targeted therapies have provided exciting advancements in the treatment of cancer where standard chemotherapy alone has failed. We discuss here a potential therapeutic target, the c-Jun activation domain-binding protein-1 (Jab1), which has been implicated to be involved in the tumorigenic process. Jab1 is involved in multiple protein interactions that affect many stages of tumorigenesis and, therefore, has the potential to be an effective therapeutic target.
Jab1/CSN5 was originally identified as a c-Jun coactivator and subsequently discovered to be the fifth member and an integral component of the constitutive photomorphogenic-9 (COP9) signalosome (CSN) complex, a multifunctional protein complex involved in modulating signal transduction, gene transcription, and protein stability in cells [1-3]. For this reason, Jab1 is also referred to as CSN5. Jab1/CSN5 contains an Mpr1-Pad1-N-terminal (MPN) domain metalloenzyme motif (JAMM) that is essential for the CSN isopeptidase activity responsible for the deneddylation of the cullin-RING ubiquitin ligases (CRLs) by CSN [4].
Jab1/CSN5 plays an essential role in positively regulating cellular proliferation by functionally inactivating several key negative regulatory proteins and tumor suppressors through their subcellular localization, degradation, and deneddylation, including p53, Smad 4/7, and the cyclin-dependent kinase inhibitor p27Kip1 (p27) [5-8]. It is also capable of stabilizing certain proteins, including hypoxia-inducible factor 1a (HIF-1α) and c-Jun, as well as acting as a transcriptional co-factor for MYC, which is responsible for the transcriptional activation of genes involved in cell proliferation, angiogenesis, and invasion [1,9,10]. Jab1/CSN5 overexpression has been identified in a number of tumor types and has been implicated in the initiation and progression of several types of cancer.
Jab1/CSN5 structure and function
The Jab1/CSN5 gene is highly conserved and extensively studied in mice. The murine Jab1/CSN5 gene is located on chromosome 2, whereas the human Jab1/CSN5 gene is located on chromosome 8 (Figure (Figure1A).1A). The human Jab1/CSN5 protein consists of 334 amino acids and has a molecular mass of 38 kDa (Figure 1A, B). While there are two Arabidopsis Jab1/CSN5 homologue genes, AJH1 and AJH2, there is only one known isoform in humans [11,12]. Jab1/CSN5 is evolutionarily conserved in humans, mice, fission yeast, and plants, which provides evidence that Jab1/CSN5 is critical to cell survival and proliferation [13-15]. Jab1/CSN5 was linked to the CSN through the discovery that the fifth member of the CSN was, in fact, Jab1/CSN5 and also when AJH1 and AJH2, which encode subunit 5 of the CSN, were identified in Arabidopsis [11,12,14]. Jab1/CSN5 has subsequently been termed the CSN subunit 5 (CSN5) [16].
Figure 1
Figure 1
Structure of the Jab1/CSN5 gene and domains of the Jab1/CSN5 protein. (A) Schematic of the Jab1/CSN5 gene which is 33 kb long and localized at chromosome 8Q13.2. (B) The 8 exons within the 334 amino acid sequence are shown. (C) Schematic of Jab1/CSN5 (more ...)
Jab1/CSN5 is present in the large CSN holocomplex, smaller complexes, and as a monomer in Arabidopsis, Drosophila, and mammalian cells [8,12,17,18]. Whereas CSN-associated Jab1/CSN5 is located primarily in the nucleus, free-form Jab1/CSN5 can be both cytoplasmic and nuclear. Attempts to further study the presence of Jab1/CSN5 in these complexes have been made. Separation of the CSN and the smaller complex by gel filtration method or by the nondenaturing polyacrylamide gel electrophoresis (native-PAGE) technique has proven to be a valuable tool for analyzing the presence of Jab1/CSN5 in these complexes [8,17,19]. These studies have provided valuable information about the localization and stability of Jab1/CSN5; however, the overall picture of when Jab1/CSN5 as a member of the large or small complex or in its free form and the effect on various cellular processes remains to be studied.
The domains responsible for Jab1/CSN5's interaction with p27 and its metalloproteinase activity have been identified and are shown in Figure Figure1C.1C. Jab1/CSN5 directly binds to p27 and mediates p27's shuttling between the nucleus and the cytoplasm in a CRM1-dependent manner through a nuclear export signal (NES)-like sequence between amino acids 233 and 242 at its C-terminal end [8]. Jab1/CSN5 has a Mpr1-Pad1-N (MPN) terminal domain that contains a Jab1/CSN5 MPN domain metalloenzyme (JAMM) motif (also known as the MPN+ motif). It has been postulated that the Jab1/CSN5 MPN domain serves as a protein-protein platform, while the JAMM motif acts as a cofactor for enzymatic activity [20]. The JAMM motif within Jab1/CSN5 appears to be key to CSN deneddylation activity, but deneddylation is still reliant on the entire CSN complex, as the loss of any one of the CSN subunits results in loss of this activity [20]. The JAMM motif is required for Jab1/CSN5's co-activation of the oncogenic MYC transcription factor and for Jab1/CSN5's transformative effects in a breast epithelial model, this was also found to be dependent of the assembly of the entire COP9 signalosome [21]. This domain does not, however, appear to be critical to Jab1/CSN5's functions outside of the full CSN, such as the stabilization of HIF-1α and its role as a co-factor for E2F1 apoptotic function [9,22]. In fact, the domains responsible for many of Jab1/CSN5's interactions and the mechanism by which it performs its many functions, as well as the involvement of the COP9 signalosome or small complex, remain to be determined. Elucidation of these domains will provide important insights that will further characterize the mechanisms of Jab1/CSN5 as well as the CSN.
Jab1/CSN5 is a member of the CSN
The CSN is a multisubunit complex that controls protein stability by regulation of the CRL family and is also a regulator of many cellular and developmental processes, including cell-cycle control, transcription, and DNA-damage response (please refer to reviews for more detailed information [20,23-25]. The CSN consists of 8 subunits and forms a large, 450- to 550-kDa holocomplex as well as smaller (250- to 300-kDa) cytoplasm-localized complexes containing a subset of CSN subunits (CSN-4, -5, -6, -7b, and -8 in mammals) [8,17,26]. Jab1/CSN5 is one of two members of the CSN that contain the MPN domain.
Jab1/CSN5 is a key CSN subunit, able to integrate multiple functions of the CSN complex [3]. The CSN regulation of the CRL family of ubiquitin E3 complexes relies on its deneddylation function [23,27,28]. The JAMM domain present within Jab1/CSN5 which is the catalytic center for the CSN's cleavage of the ubiquitin-like protein Nedd8 from the Cul1 subunit of the SCF ubiquitin ligases [4] is the same domain present in the 26S proteasome lid component, RPN11, and is responsible for the proteasome's cleavage of the ubiquitin substrate [29,30]. Jab1/CSN5 alone does not have metalloproteinase activity; other CSN subunits, or perhaps the entire complex, are required for this deneddylase activity [4,23,25]. The JAMM domain also has deubiquitinase activity, which regulates ubiquitinated protein sorting into exosomes when Jab1/CSN5 is associated with the CSN [31]. This links the CSN with the regulation of ubiquitinated proteins that are transferred by exosomes, a process that impacts the flow of information from neighboring or distant cells.
Jab1/CSN5 as a coactivator
Jab1/CSN5 was initially identified as a coactivator of c-Jun, a member of the activating protein-1 (AP-1) complex [1]. Members of the Jun (c-Jun, JunB, JunD) and Fos (c-Fos, FosB, Fra-1 and Fra-2) families form the AP-1 complex, which acts as a mitogen-activated composite transcription factor that has binding sites know as TPA (phorbol diester, 12-O-tetradecanoylphorbol-13-acetate)-responsive element (TRE) in a variety of promoters that activate various target genes. The AP-1 complex can respond immediately to many different extracellular stimuli, such as tumor-promoting TPA, epidermal growth factor (EGF), and serum [32]. Although c-Jun and c-Fos have very similar DNA binding and dimerization domains, they seem to activate distinct sets of target genes that only partially overlap [33-35]. Jab1/CSN5 can specifically stabilize the protein-DNA complexes on the off-rate of c-Jun and JunD with its cognate AP-1 DNA binding sites and potentiate c-Jun transactivation; however, Jab1/CSN5 does not affect JunB or v-Jun binding [1]. Jab1/CSN5's stabilization of c-Jun offers a mechanism of specificity in the binding of c-Jun to target genes.
Jab1/CSN5 is involved in c-Jun-induced, AP-1-mediated transcriptional activation through its interaction with c-Jun as well as affecting the interaction between c-Jun and other binding partners [1,36-38]. Jab1/CSN5 affects other proteins and their interaction with c-Jun by binding directly to and changing their sub-cellular localization. These interactions have been identified with the following proteins and in general lead to activation of AP-1: lymphocyte function-associated antigen-1 (LFA-1) [36,39], macrophage migration inhibitory factor (MIF) [40], hepatopoietin [41], and hepatitis B virus X protein (HBx) [42]. c-Jun is a well known oncogene whose aberrant expression and activity have been detected in cancer [32,43-46]. Because c-Jun expression is autoregulated, one can imagine that Jab1/CSN5, as a c-Jun-coregulator, may reinforce this positive-feedback loop at the transcriptional level and drive c-Jun protein expression further to promote tumorigenesis.
Jab1/CSN5's involvement as a specificity factor has been demonstrated for a number of proteins in addition to c-Jun. Jab1/CSN5 is a transcriptional coactivator and potential specificity factor for nuclear factor-kappaB (NF-κB), p53 binding protein 1 (53BP1), Brain-2 (Brn-2), and heart and neural crest derivatives expressed 2 (HAND2) signaling [37,47-50]. Jab1/CSN5 also has been shown to interact with the proto-oncogene Bcl-3, a member of the IκB family of inhibitory proteins and is present predominantly in the nucleus. While most members of the IκB family act to inhibit NF-κB, Bcl-3 can activate NF-κB transcription. Jab1/CSN5 binds to Bcl-3 to enhance NF-κB, p50, and DNA complex formation and may link NF-κB and AP-1 gene transcription [47]. Another example of Jab1/CSN5 as a specificity factor is its binding to the HAND2 HLH domain and stabilization of the HAND2-E-protein 12 complex on DNA and potential involvement in promoting gene expression during neuronal development [50]. Jab1/CSN5 was also found to bind directly to 53BP1 and, under mitotic stress conditions, is required for the hyperphosphorylation resulting in activation of the mitotic checkpoint mechanism [48]. Interaction of Jab1/CSN5 with Brn-2, a transcription factor expressed in the developing neocortex, was postulated to play a role in Brn-2-related neuronal development and, potentially, in the development of neurodegenerative diseases such as Parkinson's disease and Alzheimer's disease [49]. Jab1/CSN5 also acts as a bridge between coactivators and receptors in the progesterone receptor-steroid receptor coactivator complex [37].
These studies provide evidence of the role of Jab1/CSN5 as a specificity factor, yet the mechanism by which it acts is poorly defined. Phosphorylation is one mechanism of regulation that could be attributed to Jab1/CSN5's activation of kinases such as the Jun N-terminal kinase (JNK), which was reported to lead to increased phosphorylation of c-Jun, or through activation of kinases associated with the CSN [51,52]. Other transcription factors phosphorylated by the CSN include AP-1 and NF-kB. Also, the CSN itself has been characterized as a transcriptional regulator, recent data suggest that the CSN may be associated with chromatin [24]. Another mechanism involves the CSN's regulation of protein stability through ubiquitination of transcription factors. Whether Jab1/CSN5 functions independently as specificity factor or is mediated by functions of the COP9 signalosome has yet to be determined.
Jab1/CSN5 a positive regulator of cell cycle progression
Jab1/CSN5 promotes cell proliferation by interacting directly with p27Kip1 (p27) and induces nuclear export and subsequent p27-degradation. p27 is a critical component of the cell-cycle machinery [53]. As an inhibitor of cyclin E-Cdk2, p27 plays a pivotal role in controlling cell proliferation and therefore the cell's entry into S phase and exit from G1 phase during development and tumorigenesis [54,55]. Although p27 is haploinsufficient for tumor suppression, low levels of the protein have been identified in several cancers [56]. In addition, p27's cytoplasmic translocalization has been observed in human tumors and is associated with poor survival [57-61]. Jab1/CSN5's nuclear to cytoplasmic shuttling of p27 play an important role in the regulation and function of p27. Accumulation of cytoplasmic p27 results in increased cell motility and migration through its interaction with RhoA, a GTPase that regulates cell motility by reorganization of actin filaments [62,63]. Therefore Jab1/CSN5's role in p27 cellular localization interrupts p27's inhibitory effect on cellular proliferation and also puts it in position to interact with RhoA to mediate cell motility and migration which has an overall tumorigenic effect on the cell. In post-translational control, Jab1/CSN5--either alone or as a member of the CSN--plays an important role as a mediator of nuclear export and subsequent degradation of p27. Other Jab1/CSN5 interactions also act to enhance or inhibit Jab1/CSN5-mediated p27 degradation and are listed in Table Table11.
Table 1
Table 1
Jab1/CSN5-interacting proteins that regulate p27
Jab1/CSN5 as a modulator of intracellular signaling
Jab1/CSN5 binds numerous proteins, generally resulting in cell proliferation, survival and in some cases angiogenesis and invasion. Table Table22 summarizes these interactions that contributed to Jab1/CSN5's role in intracellular distribution, as a transcriptional activator, a member of the COP9 signalosome as well as novel Jab1/CSN5 interactions. Certainly, Jab1/CSN5's role in nuclear to cytoplasmic shuttling and subsequent degradation is widely known and affects many important proteins and tumor suppressors including p27, p53, and Smad 7, to name a few. Figure Figure22 outlines many of these interactions that act to positively or negatively regulate a number of signaling pathways in the cell.
Table 2
Table 2
Proteins that interact with Jab1/CSN5
Figure 2
Figure 2
Regulation and targets of Jab1/CSN5. Green arrows and plus (+) signs indicate Jab1/CSN5-positive interaction; red arrows and minus (-) signs indicate Jab1/CSN5-negative interaction. Abbreviations: AP-1, activator protein 1; HIF-1α, hypoxia inducible (more ...)
Jab1/CSN5 affects transforming growth factor-β (TGF-β) signaling by inducing degradation of two key downstream molecules, Smad4 and Smad7. Although TGF-β signaling can be tumor suppressive by inducing cell cycle arrest, differentiation, and apoptosis, it can be influenced by various factors in the tumor microenvironment as well as the tumor itself to, in fact, promote growth, invasion, and metastasis and contribute to the tumorigenic process [64,65]. The receptor-regulated Smad proteins (R-Smads) mediate TGF-β signaling through binding the common Smad, Smad 4, translocating to the nucleus, and mediating transcription of various genes [66]. Negative regulation of TGF-β signaling by inhibitor Smads (I-Smads), including Smad6 and Smad7, acts to interfere with the activation of the R-Smads [67,68]. Jab1/CSN5-induced Smad4 degradation results in reduced TGF-β-mediated gene transcription, whereas its degradation of Smad7 leads to enhanced TGF-β signaling effects [7,69]. It is therefore possible that connections exist between Jab1/CSN5 and TGF-β signaling that likely involve the COP9 signalosome. It is possible that overexpression of Jab1/CSN5 during the tumorigenic process results in enhanced TGF-β signaling that contributes to the progression of the disease.
Jab1/CSN5 has been implicated in apoptosis, DNA checkpoint and damage repair through a number of these protein interactions. Jab1/CSN5 can mediate the nuclear export and cytoplasmic degradation of the tumor suppressor p53 and enhances MDM2-mediated p53 ubiquitination [6]. It also mediates the degradation of the Rad9-Rad1-Hus (9-1-1) complex, thus impairing DNA checkpoint and repair in response to damage [70]. Recently, loss of Jab1/CSN5 results in spontaneous DNA breaks that was associated with increased expression of the histone H2AX, which recognized DNA double strand breaks and initiates recruitment of DNA damage repair proteins [71]. This is coupled with a deficiency in homologous recombination repair due to decreased Rad51 expression and function [71]. Taken together, these interactions provide evidence of Jab1/CSN5 as an inhibitor of DNA checkpoint and damage repair and an instigator of apoptosis. However, Jab1/CSN5's interaction with the transcription factor E2F-1 acted to synergistically induces apoptosis [22].
An interesting connection between Jab1/CSN5 and the hypoxia-inducible factor 1 alpha (HIF-1α) highlights Jab1/CSN5's potential involvement in the angiogenic pathway. HIF-1α is an oxygen-dependent transcriptional activator that is rapidly degraded under normoxic conditions, but under hypoxic conditions, it acts as a master regulator of a number of hypoxia-inducible genes, including those that are involved in angiogenesis and in cell proliferation, survival, and metabolism [72]. Jab1/CSN5 was found to compete with p53 to bind directly to the oxygen-dependent death domain of HIF-1α, leading to stabilization of HIF-1α by blocking hypoxia-dependent p53-mediated degradation [9]. In addition to stabilization of HIF-α, Jab1/CSN5 binding results in an increase in its transcriptional activity, resulting in increased VEGF expression [9]. This interaction between Jab1/CSN5 and HIF-1α suggest that Jab1/CSN5 is involved in the angiogenic pathway.
Taken together, many of these interactions are oncogenic and result in aberrant signaling involved in cell cycle progression, TGF-β signaling, angiogenesis, DNA checkpoint and repair, and apoptosis. These interactions themselves are often ill defined, and the role of the COP9 signalosome is not always clear. Further studies will need to be undertaken to identify the exact mechanisms taking place and to better define the role of Jab1/CSN5 in normal developmental processes as well as in tumorigenesis.
Regulation of Jab1/CSN5's activity
One of the potentially oncogenic mechanisms of JAB1/CSN5 overexpression is through gene amplification by an increase in the DNA copy number. The JAB1/CSN5 locus is located on chromosome 8q13.1, a region that is frequently amplified in breast, prostate, colorectal and ovarian cancers [73-77], which has also been linked to aggressive cancer phenotypes and metastatic progression [10,78].
A few proteins have been shown to regulate Jab1/CSN5 levels, localization, or activity (Table (Table2).2). Psoriasin (S100A7), a small calcium-binding protein that is highly expressed in early breast cancer, enhances Jab1/CSN5 activity and promotes tumorigenesis [79,80]. Overexpression of psoriasin increases nuclear Jab1/CSN5 activity, resulting in increased AP-1 activity and reduced p27 expression [80]. The human epidermal growth factor receptor 2 (HER2) oncogene increases expression of Jab1/CSN5 through the AKT signaling pathway via the binding of the transcription factor β-catenin and transcription factor 4 (TCF-4) to the Jab1/CSN5 promoter [81]. Treatment with wortmannin, a phosphoinositide 3-kinase (PI3K)/AKT inhibitor, subsequently reduced Jab1/CSN5 expression [81]. Additionally, the oncogenic tyrosine kinase Bcr-Abl, which is a key contributor to the development of chronic myelogenous leukemia (CML), was found to be another key regulator of Jab1/CSN5 [82]. Bcr-Abl-expressing cells have higher levels of a cytoplasmic Jab1/CSN5-containing small complex were reduced on inhibition of the Bcr-abl kinase, the mitogen-activated protein (MAP) kinase, and the PI3K signaling pathways [82]. In another study, the peroxisome proliferator-activated receptor γ (PPAR γ) suppressed Jab1/CSN5 promoter activity in both PPAR γ-dependent and -independent manners [83]. These studies have linked Jab1/CSN5 expression and activity with well-known oncogenes and suggest that Jab1/CSN5 activities are involved in the progression of cancer. However, these oncogenes are fairly cancer specific and given the wide range of cancers that Jab1/CSN5 is found to be overexpressed, it is quite possible that other mechanisms or regulation of Jab1/CSN5 expression exists.
Jab1/CSN5 in mouse models
Jab1/CSN5-deficient mice exhibit an embryonically lethal phenotype, which suggests that Jab1/CSN5 is important in development and survival. Jab1/CSN5-null embryos are viable up through the blastocyst stage but begin to exhibit disrupted development at embryonic day 6.0 and are no longer viable at day 8.5, before gastrulation occurs [71,84]. Several targets of Jab1/CSN5, including p27, p53, c-myc, and cyclin E, were found to be highly expressed in Jab1/CSN5-/- embryos, resulting in impaired proliferation and accelerated apoptosis [71,84]. By building on these findings, we found that Jab1/CSN5 sensitized mouse embryonic fibroblasts to gamma radiation-induced apoptosis and increased spontaneous DNA damage that could be attributed to reduced levels of the DNA repair protein Rad51 and increased levels of p53 [71]. We found that in the absence of exogenous DNA damage, Jab1/CSN5-deficient embryos and osteosarcoma cells showed increased incidence of a spontaneous genome instability phenotype: findings included a large number of TUNEL foci in Jab1/CSN5-null embryos embryos and blastocysts and an increased number of γ-H2AX foci with a decreased percentage of intact DNA in Jab1/CSN5-deficient mouse embryonic fibroblasts and in human osteosarcoma cells [71]. These findings suggested that Jab1/CSN5-deficient cells promote spontaneous DNA breaks; therefore, loss of Jab1/CSN5 may affect efficient DNA repair. The results of these studies indicate that Jab1/CSN5 is essential for efficient DNA repair and mechanistically link Jab1/CSN5 to the maintenance of genome integrity and to cell survival.
Jab1/CSN5 was conditionally deleted to determine its role in cell cycle regulation, apoptosis, and DNA repair processes that are critical for developing thymocytes [85]. Conditional deletion of Jab1/CSN5 in thymocytes resulted in defective S-phase progression and increased apoptosis that could be attributed to CSN substrates, including p53, IκB-α, and β-catenin. These results confirmed the importance of Jab1/CSN5 in coordinating the process involved in the development and positive selection of T cells. Further, these findings provided some support for the conceptual premise that Jab1/CSN5, along with the rest of the CSN, orchestrates the development of various tissues by maintaining the balance between proliferation and survival throughout various checkpoints in the process.
Overexpression of Jab1/CSN5 in a transgenic mouse model was linked to myeloproliferative disease. Those mice showed enhanced proliferation and maintenance of hematopoietic progenitors [86]. Inversely, the results from additional studies suggest that inhibition of Jab1/CSN5 by siRNA results in delayed tumor growth in murine xenografts, a finding that justifies further investigation of Jab1/CSN5 as a potential therapeutic target [87].
Jab1/CSN5 in cancer
Jab1/CSN5 has been implicated in the pathogenesis in several cancer types and in many cases, specifically correlated with reduced levels of p27 and poor prognosis. Because of emerging recognition of its role in negatively controlling p27 activity, recent pre-clinical studies have implicated Jab1/CSN5 function in the pathogenesis of human cancers. Tumors in which Jab1/CSN5 overexpression was detected are listed in Table Table3.3. Low levels of p27 protein have been associated with high expression of Jab1/CSN5 in a number of tumors (Table (Table3).3). Low p27 levels have been reported in up to 50% of all human cancers, yet no modifications in the gene have been identified, and inhibition of p27 is postulated to occur at the post-transcriptional level [88,89]. In addition to low levels of p27 expression characterizing many tumors, studies have increasingly pointed to subcellular localization of p27 through cytoplasmic translocation in human tumors associated with poor survival rates [57-61,90,91].
Table 3
Table 3
Cancers in which Jab1/CSN5 is overexpressed and its association with p27 and clinical outcome
Jab1/CSN5-mediated degradation of p27 appears to be a critical mechanism of regulation for this cell cycle inhibitor. The correlation between high Jab1/CSN5 levels and low p27 levels in a number of tumors provides further evidence that this is a common phenomenon and may contribute to the pathogenesis of these diseases. For example, Jab1/CSN5 expression was found low or absent in normal adult breast tissue, but is aberrantly expressed in 50% of primary breast tumors and 90% of metastatic lesions making an ideal target for therapeutic intervention [92,93]. Our group examined Jab1/CSN5 and p27 protein expression in invasive breast carcinoma specimens and their association with clinical outcome [92,93]. We immunohistochemically detected Jab1/CSN5 in 43 (81%) of 53 tumors, with 32 (60%) tumors having high levels of Jab1/CSN5 expression (>50% of cells positive for Jab1/CSN5), but reduced or absent p27 expression (P = 0.02). Breast tumors with high levels of p27 expression were rarely positive for Jab1/CSN5 expression. Furthermore, Jab1/CSN5 protein expression levels were higher in oncogenically transformed breast cells and tumors than in normal mammary epithelial specimens. Furthermore, adenovirally mediated Jab1/CSN5 overexpression in breast cancer cells reduced p27 expression levels by accelerating p27 degradation. Importantly, patients with Jab1/CSN5-negative tumors had no evidence of relapse or disease progression at a median follow-up duration of 70 months [92]. These results correlate with the known molecular function of Jab1/CSN5 in relocalizing p27 from the nucleus to the cytoplasm, thereby promoting degradation of p27 through the ubiquitin/proteasome pathway, allowing breast tumor cells to progress into S phase.
There were also a small number of cases in which high Jab1/CSN5 expression did not correlate with low p27 expression. Other factors, such as the ubiquitin ligase, S-phase kinase-associated protein 2 (Skp2), are known to regulate p27 and have also been found to correlate with p27 expression in cancer. In one study, Skp2 expression correlated with reduced p27 in epithelial ovarian tumors, and although Skp2 alone was associated with poor prognosis, evaluation of the combined phenotype, Skp2(+) Jab1/CSN5(+) p27(-), led to identification of patients with the worst prognosis [94]. Given the importance of p27 degradation in cancer, development of a therapy to inhibit Jab1/CSN5 is likely to be clinically valuable.
While the connection between Jab1/CSN5 overexpression and reduced p27 is evident in human tumors, the correlation between Jab1/CSN5 and c-Jun activation, while apparent in preclinical studies, has yet to be validated in human specimens. Jun is a well-characterized oncogene that has been demonstrated to promote cellular proliferation and invasion in certain tissues [95,96]. Expression of c-Jun is evident and has proven to have prognostic value in a number of tumor types and to contribute to carcinogenesis [43-46]. Further, c-Jun is also downstream of a number of signaling cascades and therefore contributes to the process of oncogenesis even when expressed at normal levels [34]. While the link between Jab1/CSN5 overexpression in tumors and c-Jun activation has not been clearly identified in patient samples, our preclinical studies suggest that this correlation exists. High AP-1 activity was detected in Jab1/CSN5 overexpressing xenograft models (data not shown). Future studies to investigate this correlation in tumor samples would be useful in validating these findings.
Importantly, Jab1/CSN5/CSN5, alongside Myc, was found to act as a master regulator of a wound gene expression signature in breast cancer cells. This study suggests that Jab1/CSN5 plays an important role in translating the cell stress response to transcription of response genes that are involved in proliferation and matrix invasiveness [10]. Jab1/CSN5's location on chromosome 8q, which is frequently amplified during the progression of cancer and its function as a master regulator alongside Myc highlight the possibility that Jab1/CSN5 is a candidate oncogene. This DNA copy number gain of Jab1/CSN5 was confirmed in a study of hepatocellular carcinoma that correlated with amplification of the 8q region [97]. This suggests that the location of Jab1/CSN5 in this highly amplified region may be one mechanism leading to its overexpression in cancer.
Jab1/CSN5's role in breast cancer is increasingly becoming clearer. Studies have demonstrated Jab1/CSN5 overexpression in breast cancer [92,98,99]. The breast cancer driving EGFR receptors including the oncogenic HER2/neu have been correlated with increased Jab1/CSN5 expression in clinical samples [98,99]. Jab1/CSN5 was shown to be a target of EGFR signaling in estrogen receptor-alpha-negative (ERα-) breast cancer and the translocation of Jab1/CSN5 to the nucleus was shown to be mediated through the ERK signaling pathway [98]. Similarly, HER-2/neu was found to activate Jab1/CSN5 expression through the AKT/bet-catenin pathway [99]. The involvement of Jab1/CSN5 in breast tumorigenesis appears to be linked to the expression of EGFR and HER-2/neu receptors and may in part mediate downstream signaling events that contribute to the progression of tumor growth.
The detection of Jab1/CSN5 overexpression in a variety of human tumors suggests that it is a significant contributor to the tumorigenic process. Results from preclinical studies (and unpublished data) also provide evidence that Jab1/CSN5 is playing an important role in this process (references in Table Table3).3). In a recent study by Adler et al, they investigated the ability of Jab1/CSN5 to promote breast epithelial transformation and also linked the biochemical activities of Jab1/CSN5. They found that Jab1/CSN5 indeed had transforming capabilities that was dependent on both the assembly of the COP9 signalosome and also the isopeptidase activity present in JAMM motif of Jab1/CSN5 [21]. Jab1/CSN5 is found to be overexpressed in a number of human tumors, but whether this overexpression is sufficient to mediate the tumorigenic process was tested in a transgenic mouse model. Intriguingly, mice overexpressing a modified Jab1/CSN5 show that the level of Jab1/CSN5 expression is a critical determinant of the proliferation and maintenance of hematopoietic progenitor cells in vivo, which may explain how the overexpression of Jab1/CSN5 contributes to tumor development [86]. It was postulated that perhaps an initial DNA damaging event, activation of an oncogene or alternatively inhibition of a tumor suppressor could be necessary for Jab1/CSN5 to mediate its tumorigenic effects. Additional studies suggest that depletion of Jab1/CSN5 is able to reduce proliferation in pancreatic cancer cells [100]. These data suggest that overexpression of Jab1/CSN5 contributes to the development of tumors and that inhibition of Jab1/CSN5 is sufficient to impact on proliferation and potentially other properties of tumors and warrants further investigation as a cancer therapeutic.
Jab1/CSN5's multiple functions affect a number of proteins and signaling pathways, and the results of these interactions are generally oncogenic. The strong correlation between Jab1/CSN5 overexpression and low p27 levels and poor prognosis in a variety of human cancers underscores the importance of Jab1/CSN5 in carcinogenesis. However, the exact role that Jab1/CSN5 plays in oncogenic processes and which of its many functions contributes to these processes is far from being fully understood. It would be interesting to determine whether Jab1/CSN5 contributes to tumorigenesis through one specific interaction or the accumulation of multiple interactions. Further, whether these interactions are dependent on Jab1/CSN5's existence as either a member of the COP9 signalosome holo-complex or a member of smaller complexes outside the COP9 signalosome, which contain other members of the CSN, or its presence as a monomer, has yet to be clarified.
The physiologic significance of Jab1/CSN5 in cancer is highlighted by the wide range of cancers in which it is overexpressed. Yet the molecular mechanism by which Jab1/CSN5 is involved in the myriad of protein interactions remains to be more clearly identified. No particular protein domain identified within these proteins links them in any way. The JAMM domain is certainly important for cleavage of cullin-Nedd8 conjugates and represent a major player in cellular regulation, but it does not appear to be the key domain for all Jab1/CSN5 interactions. It has been suggested that a post-translational modification or possibly a redox-induced protein modification leads to a Jab1/CSN5 interaction; this warrants further investigation [101]. A link between the Ras/MAPK and PI3K/AKT pathways, which were detected through Bcr-Abl signaling, has been identified. Understanding the mechanisms of activation will be critical for understanding the regulation of Jab1/CSN5's functions. These mechanisms also involve interactions between the CSN and other large protein complexes as have been demonstrated with Iκ-B kinases and suggested to occur with nuclear receptors and their coactivators [37,102].
Much remains unclear about Jab1/CSN5, but what is clear is that its overexpression is involved in the development of cancer and that further investigation of Jab1/CSN5 as a therapeutic target may lead to the development of a powerful cancer therapeutic for use in a wide range of tumors.
Conflict of interests
The authors declare that they have no competing interests.
Authors' contributions
All authors have contributed to the writing of this paper. They have read and approved the final manuscript.
Acknowledgements
We thank Drs Q. Zhang, L. Tian and A. Korapati for providing helpful comments on the manuscript. T.J.S. is a recipient of fellowships from Susan G. Komen for the Cure and the Department of Defense US Army Breast Cancer Research Program. This work was supported by grants from the National Cancer Institute (CA90853-01A1), U.S. Department of Defense, and the Susan G. Komen for the Cure to F.X.C.
  • Claret FX, Hibi M, Dhut S, Toda T, Karin M. A new group of conserved coactivators that increase the specificity of AP-1 transcription factors. Nature. 1996;383:453–457. doi: 10.1038/383453a0. [PubMed] [Cross Ref]
  • Schwechheimer C, Deng XW. COP9 signalosome revisited: a novel mediator of protein degradation. Trends Cell Biol. 2001;11:420–426. doi: 10.1016/S0962-8924(01)02091-8. [PubMed] [Cross Ref]
  • Chamovitz DA, Segal D. JAB1/CSN5 and the COP9 signalosome. A complex situation. EMBO Rep. 2001;2:96–101. doi: 10.1093/embo-reports/kve028. [PubMed] [Cross Ref]
  • Cope G, Suh GS, Aravind L, Schwarz SE, Zipursky SL, Koonin EV, Deshaies RJ. Role of predicted metalloprotease motif of Jab1/Csn5 in cleavage of Nedd8 from Cul1. Science. 2002;298:608–611. doi: 10.1126/science.1075901. [PubMed] [Cross Ref]
  • Bech-Otschir D, Kraft R, Huang X, Henklein P, Kapelari B, Pollmann C, Dubiel W. COP9 signalosome-specific phosphorylation targets p53 to degradation by the ubiquitin system. Embo J. 2001;20:1630–1639. doi: 10.1093/emboj/20.7.1630. [PubMed] [Cross Ref]
  • Oh W, Lee EW, Sung YH, Yang MR, Ghim J, Lee HW, Song J. Jab1 induces the cytoplasmic localization and degradation of p53 in coordination with Hdm2. J Biol Chem. 2006;281:17457–17465. doi: 10.1074/jbc.M601857200. [PubMed] [Cross Ref]
  • Wan M, Cao X, Wu Y, Bai S, Wu L, Shi X, Wang N. Jab1 antagonizes TGF-beta signaling by inducing Smad4 degradation. EMBO Rep. 2002;3:171–176. doi: 10.1093/embo-reports/kvf024. [PubMed] [Cross Ref]
  • Tomoda K, Kubota Y, Arata Y, Mori S, Maeda M, Tanaka T, Yoshida M, Yoneda-Kato N, Kato J. The cytoplasmic shuttling and subsequent degradation of p27Kip1 mediated by Jab1/CSN5 and the COP9 signalosome complex. J Biol Chem. 2002;277:2302–2310. doi: 10.1074/jbc.M104431200. [PubMed] [Cross Ref]
  • Bae MK, Ahn MY, Jeong JW, Bae MH, Lee YM, Bae SK, Park JW, Kim KR, Kim KW. Jab1 interacts directly with HIF-1alpha and regulates its stability. J Biol Chem. 2002;277:9–12. doi: 10.1074/jbc.C100442200. [PubMed] [Cross Ref]
  • Adler AS, Lin M, Horlings H, Nuyten DS, van de Vijver MJ, Chang HY. Genetic regulators of large-scale transcriptional signatures in cancer. Nat Genet. 2006;38:421–430. doi: 10.1038/ng1752. [PMC free article] [PubMed] [Cross Ref]
  • Kwok SF, Solano R, Tsuge T, Chamovitz DA, Ecker JR, Matsui M, Deng XW. Arabidopsis homologs of a c-Jun coactivator are present both in monomeric form and in the COP9 complex, and their abundance is differentially affected by the pleiotropic cop/det/fus mutations. Plant Cell. 1998;10:1779–1790. doi: 10.1105/tpc.10.11.1779. [PubMed] [Cross Ref]
  • Kwok SF, Staub JM, Deng XW. Characterization of two subunits of Arabidopsis 19S proteasome regulatory complex and its possible interaction with the COP9 complex. J Mol Biol. 1999;285:85–95. doi: 10.1006/jmbi.1998.2315. [PubMed] [Cross Ref]
  • Wei N, Tsuge T, Serino G, Dohmae N, Takio K, Matsui M, Deng XW. The COP9 complex is conserved between plants and mammals and is related to the 26S proteasome regulatory complex. Curr Biol. 1998;8:919–922. doi: 10.1016/S0960-9822(07)00372-7. [PubMed] [Cross Ref]
  • Seeger M, Kraft R, Ferrell K, Bech-Otschir D, Dumdey R, Schade R, Gordon C, Naumann M, Dubiel W. A novel protein complex involved in signal transduction possessing similarities to 26S proteasome subunits. Faseb J. 1998;12:469–478. [PubMed]
  • Wei N, Deng XW. Making sense of the COP9 signalsome: a regulatory protein complex conserved from Arabidopsis to human. Trends Genet. 1999;15:98–103. doi: 10.1016/S0168-9525(98)01670-9. [PubMed] [Cross Ref]
  • Deng XW, Dubiel W, Wei N, Hofmann K, Mundt K, Colicelli J, Kato J, Naumann M, Segal D, Seeger M, Carr A, Glickman M, Chamovitz DA. Unified nomenclature for the COP9 signalosome and its subunits: an essential regulator of development. Trends Genet. 2000;16:202–203. doi: 10.1016/S0168-9525(00)01982-X. [PubMed] [Cross Ref]
  • Fukumoto A, Tomoda K, Kubota M, Kato JY, Yoneda-Kato N. Small Jab1-containing subcomplex is regulated in an anchorage- and cell cycle-dependent manner, which is abrogated by ras transformation. FEBS Lett. 2005;579:1047–1054. doi: 10.1016/j.febslet.2004.12.076. [PubMed] [Cross Ref]
  • Oron E, Mannervik M, Rencus S, Harari-Steinberg O, Neuman-Silberberg S, Segal D, Chamovitz DA. COP9 signalosome subunits 4 and 5 regulate multiple pleiotropic pathways in Drosophila melanogaster. Development. 2002;129:4399–4409. [PubMed]
  • Bounpheng MA, Melnikova IN, Dodds SG, Chen H, Copeland NG, Gilbert DJ, Jenkins NA, Christy BA. Characterization of the mouse JAB1 cDNA and protein. Gene. 2000;242:41–50. doi: 10.1016/S0378-1119(99)00525-9. [PubMed] [Cross Ref]
  • Wei N, Serino G, Deng XW. The COP9 signalosome: more than a protease. Trends Biochem Sci. 2008;33:592–600. doi: 10.1016/j.tibs.2008.09.004. [PubMed] [Cross Ref]
  • Adler AS, Littlepage LE, Lin M, Kawahara TL, Wong DJ, Werb Z, Chang HY. CSN5 isopeptidase activity links COP9 signalosome activation to breast cancer progression. Cancer Res. 2008;68:506–515. doi: 10.1158/0008-5472.CAN-07-3060. [PMC free article] [PubMed] [Cross Ref]
  • Hallstrom TC, Nevins JR. Jab1 is a specificity factor for E2F1-induced apoptosis. Genes Dev. 2006;20:613–623. doi: 10.1101/gad.1345006. [PubMed] [Cross Ref]
  • Cope GA, Deshaies RJ. COP9 signalosome: a multifunctional regulator of SCF and other cullin-based ubiquitin ligases. Cell. 2003;114:663–671. doi: 10.1016/S0092-8674(03)00722-0. [PubMed] [Cross Ref]
  • Chamovitz DA. Revisiting the COP9 signalosome as a transcriptional regulator. EMBO Rep. 2009;10:352–358. doi: 10.1038/embor.2009.33. [PubMed] [Cross Ref]
  • Kato JY, Yoneda-Kato N. Mammalian COP9 signalosome. Genes Cells. 2009;14:1209–1225. doi: 10.1111/j.1365-2443.2009.01349.x. [PubMed] [Cross Ref]
  • Wei N, Deng XW. The COP9 signalosome. Annu Rev Cell Dev Biol. 2003;19:261–286. doi: 10.1146/annurev.cellbio.19.111301.112449. [PubMed] [Cross Ref]
  • Wolf DA, Zhou C, Wee S. The COP9 signalosome: an assembly and maintenance platform for cullin ubiquitin ligases? Nat Cell Biol. 2003;5:1029–1033. doi: 10.1038/ncb1203-1029. [PubMed] [Cross Ref]
  • Dubiel W. Resolving the CSN and CAND1 paradoxes. Mol Cell. 2009;35:547–549. doi: 10.1016/j.molcel.2009.08.011. [PubMed] [Cross Ref]
  • Maytal-Kivity V, Reis N, Hofmann K, Glickman MH. MPN+, a putative catalytic motif found in a subset of MPN domain proteins from eukaryotes and prokaryotes, is critical for Rpn11 function. BMC Biochem. 2002;3:28. doi: 10.1186/1471-2091-3-28. [PMC free article] [PubMed] [Cross Ref]
  • Verma R, Aravind L, Oania R, McDonald WH, Yates JR, Koonin EV, Deshaies RJ. Role of Rpn11 metalloprotease in deubiquitination and degradation by the 26S proteasome. Science. 2002;298:611–615. doi: 10.1126/science.1075898. [PubMed] [Cross Ref]
  • Liu Y, Shah SV, Xiang X, Wang J, Deng ZB, Liu C, Zhang L, Wu J, Edmonds T, Jambor C, Kappes JC, Zhang HG. COP9-associated CSN5 regulates exosomal protein deubiquitination and sorting. Am J Pathol. 2009;174:1415–1425. doi: 10.2353/ajpath.2009.080861. [PubMed] [Cross Ref]
  • Shaulian E, Karin M. AP-1 in cell proliferation and survival. Oncogene. 2001;20:2390–2400. doi: 10.1038/sj.onc.1204383. [PubMed] [Cross Ref]
  • Jochum W, Passegue E, Wagner EF. AP-1 in mouse development and tumorigenesis. Oncogene. 2001;20:2401–2412. doi: 10.1038/sj.onc.1204389. [PubMed] [Cross Ref]
  • Vogt PK. Jun, the oncoprotein. Oncogene. 2001;20:2365–2377. doi: 10.1038/sj.onc.1204443. [PubMed] [Cross Ref]
  • Eferl R, Wagner EF. AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer. 2003;3:859–868. doi: 10.1038/nrc1209. [PubMed] [Cross Ref]
  • Bianchi E, Denti S, Granata A, Bossi G, Geginat J, Villa A, Rogge L, Pardi R. Integrin LFA-1 interacts with the transcriptional co-activator JAB1 to modulate AP-1 activity. Nature. 2000;404:617–621. doi: 10.1038/35007098. [PubMed] [Cross Ref]
  • Chauchereau A, Georgiakaki M, Perrin-Wolff M, Milgrom E, Loosfelt H. JAB1 interacts with both the progesterone receptor and SRC-1. J Biol Chem. 2000;275:8540–8548. doi: 10.1074/jbc.275.12.8540. [PubMed] [Cross Ref]
  • Li S, Liu X, Ascoli M. p38JAB1 binds to the intracellular precursor of the lutropin/choriogonadotropin receptor and promotes its degradation. J Biol Chem. 2000;275:13386–13393. doi: 10.1074/jbc.275.18.13386. [PubMed] [Cross Ref]
  • Levinson H, Sil AK, Conwell JE, Hopper JE, Ehrlich HP. Alpha V integrin prolongs collagenase production through Jun activation binding protein 1. Ann Plast Surg. 2004;53:155–161. doi: 10.1097/01.sap.0000112281.97409.a6. [PubMed] [Cross Ref]
  • Kleemann R, Hausser A, Geiger G, Mischke R, Burger-Kentischer A, Flieger O, Johannes FJ, Roger T, Calandra T, Kapurniotu A, Grell M, Finkelmeier D, Brunner H, Bernhagen J. Intracellular action of the cytokine MIF to modulate AP-1 activity and the cell cycle through Jab1. Nature. 2000;408:211–216. doi: 10.1038/35041591. [PubMed] [Cross Ref]
  • Lu C, Li Y, Zhao Y, Xing G, Tang F, Wang Q, Sun Y, Wei H, Yang X, Wu C, Chen J, Guan KL, Zhang C, Chen H, He F. Intracrine hepatopoietin potentiates AP-1 activity through JAB1 independent of MAPK pathway. Faseb J. 2002;16:90–92. [PubMed]
  • Tanaka Y, Kanai F, Ichimura T, Tateishi K, Asaoka Y, Guleng B, Jazag A, Ohta M, Imamura J, Ikenoue T, Ijichi H, Kawabe T, Isobe T, Omata M. The hepatitis B virus X protein enhances AP-1 activation through interaction with Jab1. Oncogene. 2006;25:633–642. doi: 10.1038/sj.onc.1209311. [PubMed] [Cross Ref]
  • Lopez-Bergami P, Lau E, Ronai Z. Emerging roles of ATF2 and the dynamic AP1 network in cancer. Nat Rev Cancer. 2010;10:65–76. doi: 10.1038/nrc2681. [PMC free article] [PubMed] [Cross Ref]
  • Gee JM, Barroso AF, Ellis IO, Robertson JF, Nicholson RI. Biological and clinical associations of c-jun activation in human breast cancer. Int J Cancer. 2000;89:177–186. doi: 10.1002/(SICI)1097-0215(20000320)89:2<177::AID-IJC13>3.0.CO;2-0. [PubMed] [Cross Ref]
  • Yokoyama Y, Sagara M, Sato S, Saito Y. Value of glutathione S-transferase pi and the oncogene products c-Jun, c-Fos, c-H-Ras, and c-Myc as a prognostic indicator in endometrial carcinomas. Gynecol Oncol. 1998;68:280–287. doi: 10.1006/gyno.1998.4936. [PubMed] [Cross Ref]
  • Tiniakos DG, Scott LE, Corbett IP, Piggott NH, Horne CH. Studies of c-jun oncogene expression in human breast using a new monoclonal antibody, NCL-DK4. J Pathol. 1994;172:19–26. doi: 10.1002/path.1711720106. [PubMed] [Cross Ref]
  • Dechend R, Hirano F, Lehmann K, Heissmeyer V, Ansieau S, Wulczyn FG, Scheidereit C, Leutz A. The Bcl-3 oncoprotein acts as a bridging factor between NF-kappaB/Rel and nuclear co-regulators. Oncogene. 1999;18:3316–3323. doi: 10.1038/sj.onc.1202717. [PubMed] [Cross Ref]
  • Kwak HJ, Kim SH, Yoo HG, Park SH, Lee CH. Jun activation domain-binding protein 1 is required for mitotic checkpoint activation via its involvement in hyperphosphorylation of 53BP1. J Cancer Res Clin Oncol. 2005;131:789–796. doi: 10.1007/s00432-005-0035-y. [PubMed] [Cross Ref]
  • Huang YT, Iwamoto K, Kurosaki T, Nasu M, Ueda S. The neuronal POU transcription factor Brn-2 interacts with Jab1, a gene involved in the onset of neurodegenerative diseases. Neurosci Lett. 2005;382:175–178. doi: 10.1016/j.neulet.2005.03.008. [PubMed] [Cross Ref]
  • Dai YS, Hao J, Bonin C, Morikawa Y, Cserjesi P. JAB1 enhances HAND2 transcriptional activity by regulating HAND2 DNA binding. J Neurosci Res. 2004;76:613–622. doi: 10.1002/jnr.20105. [PubMed] [Cross Ref]
  • Sun Y, Wilson MP, Majerus PW. Inositol 1,3,4-trisphosphate 5/6-kinase associates with the COP9 signalosome by binding to CSN1. J Biol Chem. 2002;277:45759–45764. doi: 10.1074/jbc.M208709200. [PubMed] [Cross Ref]
  • Uhle S, Medalia O, Waldron R, Dumdey R, Henklein P, Bech-Otschir D, Huang X, Berse M, Sperling J, Schade R, Dubiel W. Protein kinase CK2 and protein kinase D are associated with the COP9 signalosome. Embo J. 2003;22:1302–1312. doi: 10.1093/emboj/cdg127. [PubMed] [Cross Ref]
  • Tomoda K, Kubota Y, Kato J. Degradation of the cyclin-dependent-kinase inhibitor p27Kip1 is instigated by Jab1. Nature. 1999;398:160–165. doi: 10.1038/18230. [PubMed] [Cross Ref]
  • Toyoshima H, Hunter T. p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell. 1994;78:67–74. doi: 10.1016/0092-8674(94)90573-8. [PubMed] [Cross Ref]
  • Polyak K, Lee MH, Erdjument-Bromage H, Koff A, Roberts JM, Tempst P, Massague J. Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell. 1994;78:59–66. doi: 10.1016/0092-8674(94)90572-X. [PubMed] [Cross Ref]
  • Fero ML, Randel E, Gurley KE, Roberts JM, Kemp CJ. The murine gene p27Kip1 is haplo-insufficient for tumor suppression. Nature. 1998;396:177–180. doi: 10.1038/24179. [PubMed] [Cross Ref]
  • Loda M, Cukor B, Tam SW, Lavin P, Fiorentino M, Draetta GF, Jessup JM, Pagano M. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med. 1997;3:231–234. doi: 10.1038/nm0297-231. [PubMed] [Cross Ref]
  • Guo Y, Sklar GN, Borkowski A, Kyprianou N. Loss of the cyclin-dependent kinase inhibitor p27(Kip1) protein in human prostate cancer correlates with tumor grade. Clin Cancer Res. 1997;3:2269–2274. [PubMed]
  • Masciullo V, Sgambato A, Pacilio C, Pucci B, Ferrandina G, Palazzo J, Carbone A, Cittadini A, Mancuso S, Scambia G, Giordano A. Frequent loss of expression of the cyclin-dependent kinase inhibitor p27 in epithelial ovarian cancer. Cancer Res. 1999;59:3790–3794. [PubMed]
  • Singh SP, Lipman J, Goldman H, Ellis FH Jr, Aizenman L, Cangi MG, Signoretti S, Chiaur DS, Pagano M, Loda M. Loss or altered subcellular localization of p27 in Barrett's associated adenocarcinoma. Cancer Res. 1998;58:1730–1735. [PubMed]
  • Ciaparronne M, Yamamoto H, Yao Y, Sgambato A, Cattoretti G, Tomita N, Monden T, Rotterdam H, Weinstein IB. Localization and expression of p27KIP1 in multistage colorectal carcinogenesis. Cancer Res. 1998;58:114–122. [PubMed]
  • Larrea MD, Wander SA, Slingerland JM. p27 as Jekyll and Hyde: regulation of cell cycle and cell motility. Cell Cycle. 2009;8:3455–3461. [PubMed]
  • Bar-Sagi D, Hall A. Ras and Rho GTPases: a family reunion. Cell. 2000;103:227–238. doi: 10.1016/S0092-8674(00)00115-X. [PubMed] [Cross Ref]
  • Tian M, Schiemann WP. The TGF-beta paradox in human cancer: an update. Future Oncol. 2009;5:259–271. doi: 10.2217/14796694.5.2.259. [PMC free article] [PubMed] [Cross Ref]
  • Bierie B, Moses HL. Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer. 2006;6:506–520. doi: 10.1038/nrc1926. [PubMed] [Cross Ref]
  • Massague J, Wotton D. Transcriptional control by the TGF-beta/Smad signaling system. Embo J. 2000;19:1745–1754. doi: 10.1093/emboj/19.8.1745. [PubMed] [Cross Ref]
  • Imamura T, Takase M, Nishihara A, Oeda E, Hanai J, Kawabata M, Miyazono K. Smad6 inhibits signalling by the TGF-beta superfamily. Nature. 1997;389:622–626. doi: 10.1038/39355. [PubMed] [Cross Ref]
  • Nakao A, Afrakhte M, Moren A, Nakayama T, Christian JL, Heuchel R, Itoh S, Kawabata M, Heldin NE, Heldin CH, ten Dijke P. Identification of Smad7, a TGFbeta-inducible antagonist of TGF-beta signalling. Nature. 1997;389:631–635. doi: 10.1038/39369. [PubMed] [Cross Ref]
  • Kim BC LH, Park SH, Lee SR, Karpova TS, McNally JG, Felici A, Lee DK, Kim SJ. Jab1/CSN5, a Component of the COP9 Signalosome, Regulates Transforming Growth Factor beta Signaling by Binding to Smad7 and Promoting Its Degradation. Mol Cell Biol. 2004;24:2251–2262. doi: 10.1128/MCB.24.6.2251-2262.2004. [PMC free article] [PubMed] [Cross Ref]
  • Huang J, Yuan H, Lu C, Liu X, Cao X, Wan M. Jab1 mediates protein degradation of the Rad9-Rad1-Hus1 checkpoint complex. J Mol Biol. 2007;371:514–527. doi: 10.1016/j.jmb.2007.05.095. [PMC free article] [PubMed] [Cross Ref]
  • Tian L, Peng G, Parant JM, Leventaki V, Drakos E, Zhang Q, Parker-Thornburg J, Shackleford TJ, Dai H, Lin SY, Lozano G, Rassidakis GZ, Claret FX. Essential roles of Jab1 in cell survival, spontaneous DNA damage and DNA repair. Oncogene. 2010. [PubMed] [Cross Ref]
  • Lee JW, Bae SH, Jeong JW, Kim SH, Kim KW. Hypoxia-inducible factor (HIF-1)alpha: its protein stability and biological functions. Exp Mol Med. 2004;36:1–12. [PubMed]
  • Fejzo MS, Godfrey T, Chen C, Waldman F, Gray JW. Molecular cytogenetic analysis of consistent abnormalities at 8q12-q22 in breast cancer. Genes Chromosomes Cancer. 1998;22:105–113. doi: 10.1002/(SICI)1098-2264(199806)22:2<105::AID-GCC4>3.0.CO;2-0. [PubMed] [Cross Ref]
  • Sun J, Liu W, Adams TS, Li X, Turner AR, Chang B, Kim JW, Zheng SL, Isaacs WB, Xu J. DNA copy number alterations in prostate cancers: a combined analysis of published CGH studies. Prostate. 2007;67:692–700. doi: 10.1002/pros.20543. [PubMed] [Cross Ref]
  • Rummukainen J, Kytola S, Karhu R, Farnebo F, Larsson C, Isola JJ. Aberrations of chromosome 8 in 16 breast cancer cell lines by comparative genomic hybridization, fluorescence in situ hybridization, and spectral karyotyping. Cancer Genet Cytogenet. 2001;126:1–7. doi: 10.1016/S0165-4608(00)00387-3. [PubMed] [Cross Ref]
  • Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM, Bos JL. Genetic alterations during colorectal-tumor development. N Engl J Med. 1988;319:525–532. doi: 10.1056/NEJM198809013190901. [PubMed] [Cross Ref]
  • Dimova I, Orsetti B, Negre V, Rouge C, Ursule L, Lasorsa L, Dimitrov R, Doganov N, Toncheva D, Theillet C. Genomic markers for ovarian cancer at chromosomes 1, 8 and 17 revealed by array CGH analysis. Tumori. 2009;95:357–366. [PubMed]
  • Bieche I, Lidereau R. Genetic alterations in breast cancer. Genes Chromosomes Cancer. 1995;14:227–251. doi: 10.1002/gcc.2870140402. [PubMed] [Cross Ref]
  • Emberley ED, Niu Y, Curtis L, Troup S, Mandal SK, Myers JN, Gibson SB, Murphy LC, Watson PH. The S100A7-c-Jun activation domain binding protein 1 pathway enhances prosurvival pathways in breast cancer. Cancer Res. 2005;65:5696–5702. doi: 10.1158/0008-5472.CAN-04-3927. [PubMed] [Cross Ref]
  • Emberley ED, Niu Y, Leygue E, Tomes L, Gietz RD, Murphy LC, Watson PH. Psoriasin interacts with Jab1 and influences breast cancer progression. Cancer Res. 2003;63:1954–1961. [PubMed]
  • Hsu MC, Chang HC, Hung WC. HER-2/neu transcriptionally activates Jab1 expression via the AKT/beta-catenin pathway in breast cancer cells. Endocr Relat Cancer. 2007;14:655–667. doi: 10.1677/ERC-07-0077. [PubMed] [Cross Ref]
  • Tomoda K, Kato JY, Tatsumi E, Takahashi T, Matsuo Y, Yoneda-Kato N. The Jab1/COP9 signalosome subcomplex is a downstream mediator of Bcr-Abl kinase activity and facilitates cell-cycle progression. Blood. 2005;105:775–783. doi: 10.1182/blood-2004-04-1242. [PubMed] [Cross Ref]
  • Hsu MC, Huang CC, Chang HC, Hu TH, Hung WC. Overexpression of Jab1 in hepatocellular carcinoma and its inhibition by peroxisome proliferator-activated receptor{gamma} ligands in vitro and in vivo. Clin Cancer Res. 2008;14:4045–4052. doi: 10.1158/1078-0432.CCR-07-5040. [PubMed] [Cross Ref]
  • Tomoda K, Yoneda-Kato N, Fukumoto A, Yamanaka S, Kato JY. Multiple functions of Jab1 are required for early embryonic development and growth potential in mice. J Biol Chem. 2004;279:43013–43018. doi: 10.1074/jbc.M406559200. [PubMed] [Cross Ref]
  • Panattoni M, Sanvito F, Basso V, Doglioni C, Casorati G, Montini E, Bender JR, Mondino A, Pardi R. Targeted inactivation of the COP9 signalosome impairs multiple stages of T cell development. J Exp Med. 2008;205:465–477. doi: 10.1084/jem.20070725. [PMC free article] [PubMed] [Cross Ref]
  • Mori M, Yoneda-Kato N, Yoshida A, Kato JY. Stable form of JAB1 enhances proliferation and maintenance of hematopoietic progenitors. J Biol Chem. 2008;283:29011–29021. doi: 10.1074/jbc.M804539200. [PubMed] [Cross Ref]
  • Supriatno, Harada K, Yoshida H, Sato M. Basic investigation on the development of molecular targeting therapy against cyclin-dependent kinase inhibitor p27Kip1 in head and neck cancer cells. Int J Oncol. 2005;27:627–635. [PubMed]
  • Koff A. How to decrease p27Kip1 levels during tumor development. Cancer Cell. 2006;9:75–76. doi: 10.1016/j.ccr.2006.01.020. [PubMed] [Cross Ref]
  • Chu IM, Hengst L, Slingerland JM. The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat Rev Cancer. 2008;8:253–267. doi: 10.1038/nrc2347. [PubMed] [Cross Ref]
  • Viglietto G, Motti ML, Bruni P, Melillo RM, D'Alessio A, Califano D, Vinci F, Chiappetta G, Tsichlis P, Bellacosa A, Fusco A, Santoro. Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer. Nat Med. 2002;8:1136–1144. doi: 10.1038/nm762. [PubMed] [Cross Ref]
  • Besson A, Gurian-West M, Chen X, Kelly-Spratt KS, Kemp CJ, Roberts JM. A pathway in quiescent cells that controls p27Kip1 stability, subcellular localization, and tumor suppression. Genes Dev. 2006;20:47–64. doi: 10.1101/gad.1384406. [PubMed] [Cross Ref]
  • Kouvaraki MA, Tian L, Mansouri A, Zhang Q, Kumar R, Kittas C, Claret FX. Jun activation domain-binding protein 1 expression in breast cancer inversely correlates with the cell cycle inhibitor p27(Kip1) Cancer Res. 2003;63:2977–2981. [PubMed]
  • Esteva FJ, Sahin AA, Rassidakis GZ, Yuan LX, Smith TL, Yang Y, Gilcrease MZ, Cristofanilli M, Nahta R, Pusztai L, Claret FX. Jun activation domain binding protein 1 expression is associated with low p27(Kip1)levels in node-negative breast cancer. Clin Cancer Res. 2003;9:5652–5659. [PubMed]
  • Sui L, Dong Y, Watanabe Y, Yamaguchi F, Sugimoto K, Tokuda M. Clinical significance of Skp2 expression, alone and combined with Jab1 and p27 in epithelial ovarian tumors. Oncol Rep. 2006;15:765–771. [PubMed]
  • Smith LM, Wise SC, Hendricks DT, Sabichi AL, Bos T, Reddy P, Brown PH, Birrer MJ. cJun overexpression in MCF-7 breast cancer cells produces a tumorigenic, invasive and hormone resistant phenotype. Oncogene. 1999;18:6063–6070. doi: 10.1038/sj.onc.1202989. [PubMed] [Cross Ref]
  • Ozanne BWML, Spence HJ, Johnston I, Winnie J, Meagher L, Stapleton G. Transcriptional regulation of cell invasion: AP-1 regulation of a multigenic invasion programme. Eur J Cancer. 2000;36:1640–1648. doi: 10.1016/S0959-8049(00)00175-1. [PubMed] [Cross Ref]
  • Patil MA, Gutgemann I, Zhang J, Ho C, Cheung ST, Ginzinger D, Li R, Dykema KJ, So S, Fan ST, Kakar S, Furge KA, Buttner R, Chen X. Array-based comparative genomic hybridization reveals recurrent chromosomal aberrations and Jab1 as a potential target for 8q gain in hepatocellular carcinoma. Carcinogenesis. 2005;26:2050–2057. doi: 10.1093/carcin/bgi178. [PubMed] [Cross Ref]
  • Wang J, Barnes RO, West NR, Olson M, Chu JE, Watson PH. Jab1 is a target of EGFR signaling in ERalpha-negative breast cancer. Breast Cancer Res. 2008;10:R51. doi: 10.1186/bcr2105. [PMC free article] [PubMed] [Cross Ref]
  • Hsu MC, Chai CY, Hou MF, Chang HC, Chen WT, Hung WC. Jab1 is overexpressed in human breast cancer and is a downstream target for HER-2/neu. Mod Pathol. 2008;21:609–616. doi: 10.1038/modpathol.2008.23. [PubMed] [Cross Ref]
  • Kouvaraki MA, Korapati AL, Rassidakis GZ, Tian L, Zhang Q, Chiao P, Ho L, Evans DB, Claret FX. Potential Role of Jun Activation Domain-Binding Protein 1 as a Negative Regulator of p27kip1 in Pancreatic Adenocarcinoma. Cancer Res. 2006;66:8581–8589. doi: 10.1158/0008-5472.CAN-06-0975. [PMC free article] [PubMed] [Cross Ref]
  • Richardson KS, Zundel W. The emerging role of the COP9 signalosome in cancer. Mol Cancer Res. 2005;3:645–653. doi: 10.1158/1541-7786.MCR-05-0233. [PMC free article] [PubMed] [Cross Ref]
  • Orel L, Neumeier H, Hochrainer K, Binder BR, Schmid JA. Crosstalk between the NF-kappaB activating IKK-complex and the CSN signalosome. J Cell Mol Med. 2010;14:1555–1568. doi: 10.1111/j.1582-4934.2009.00866.x. [PubMed] [Cross Ref]
  • Caballero OL, Resto V, Patturajan M, Meerzaman D, Guo MZ, Engles J, Yochem R, Ratovitski E, Sidransky D, Jen J. Interaction and colocalization of PGP9.5 with JAB1 and p27(Kip1) Oncogene. 2002;21:3003–3010. doi: 10.1038/sj.onc.1205390. [PubMed] [Cross Ref]
  • Hwang CY, Ryu YS, Chung MS, Kim KD, Park SS, Chae SK, Chae HZ, Kwon KS. Thioredoxin modulates activator protein 1 (AP-1) activity and p27Kip1 degradation through direct interaction with Jab1. Oncogene. 2004;23:8868–8875. doi: 10.1038/sj.onc.1208116. [PubMed] [Cross Ref]
  • Jeon JH, Lee KN, Hwang CY, Kwon KS, You KH, Choi I. Tumor suppressor VDUP1 increases p27(kip1) stability by inhibiting JAB1. Cancer Res. 2005;65:4485–4489. doi: 10.1158/0008-5472.CAN-04-2271. [PubMed] [Cross Ref]
  • Hsieh YH, Su IJ, Wang HC, Tsai JH, Huang YJ, Chang WW, Lai MD, Lei HY, Huang W. Hepatitis B virus pre-S2 mutant surface antigen induces degradation of cyclin-dependent kinase inhibitor p27Kip1 through c-Jun activation domain-binding protein 1. Mol Cancer Res. 2007;5:1063–1072. doi: 10.1158/1541-7786.MCR-07-0098. [PubMed] [Cross Ref]
  • Berg JP, Zhou Q, Breuhahn K, Schirmacher P, Patil MA, Chen X, Schafer N, Holler TT, Fischer HP, Buttner R, Gutgemann I. Inverse expression of Jun activation domain binding protein 1 and cell cycle inhibitor p27Kip1: influence on proliferation in hepatocellular carcinoma. Hum Pathol. 2007;38:1621–1627. doi: 10.1016/j.humpath.2007.03.007. [PubMed] [Cross Ref]
  • Zhang XC, Chen J, Su CH, Yang HY, Lee MH. Roles for CSN5 in control of p53/MDM2 activities. J Cell Biochem. 2008;103:1219–1230. doi: 10.1002/jcb.21504. [PubMed] [Cross Ref]
  • Callige M, Kieffer I, Richard-Foy H. CSN5/Jab1 is involved in ligand-dependent degradation of estrogen receptor {alpha} by the proteasome. Mol Cell Biol. 2005;25:4349–4358. doi: 10.1128/MCB.25.11.4349-4358.2005. [PMC free article] [PubMed] [Cross Ref]
  • Doronkin S, Djagaeva I, Beckendorf SK. CSN5/Jab1 mutations affect axis formation in the Drosophila oocyte by activating a meiotic checkpoint. Development. 2002;129:5053–5064. [PubMed]
  • Kim JH, Choi JK, Cinghu S, Jang JW, Lee YS, Li YH, Goh YM, Chi XZ, Lee KS, Wee H, Bae SC. Jab1/CSN5 induces the cytoplasmic localization and degradation of RUNX3. J Cell Biochem. 2009;107:557–565. doi: 10.1002/jcb.22157. [PubMed] [Cross Ref]
  • Lue H, Thiele M, Franz J, Dahl E, Speckgens S, Leng L, Fingerle-Rowson G, Bucala R, Luscher B, Bernhagen J. Macrophage migration inhibitory factor (MIF) promotes cell survival by activation of the Akt pathway and role for CSN5/JAB1 in the control of autocrine MIF activity. Oncogene. 2007;26:5046–5059. doi: 10.1038/sj.onc.1210318. [PubMed] [Cross Ref]
  • Yun J, Tomida A, Andoh T, Tsuruo T. Interaction between glucose-regulated destruction domain of DNA topoisomerase IIalpha and MPN domain of Jab1/CSN5. J Biol Chem. 2004;279:31296–31303. doi: 10.1074/jbc.M401411200. [PubMed] [Cross Ref]
  • Nishimoto A, Lu L, Hayashi M, Nishiya T, Horinouchi T, Miwa S. Jab1 regulates levels of endothelin type A and B receptors by promoting ubiquitination and degradation. Biochem Biophys Res Commun. 2010;391:1616–1622. doi: 10.1016/j.bbrc.2009.12.087. [PubMed] [Cross Ref]
  • Bemis L, Chan DA, Finkielstein CV, Qi L, Sutphin PD, Chen X, Stenmark K, Giaccia AJ, Zundel W. Distinct aerobic and hypoxic mechanisms of HIF-alpha regulation by CSN5. Genes Dev. 2004;18:739–744. doi: 10.1101/gad.1180104. [PubMed] [Cross Ref]
  • Haag J, Aigner T. Jun activation domain-binding protein 1 binds Smad5 and inhibits bone morphogenetic protein signaling. Arthritis Rheum. 2006;54:3878–3884. doi: 10.1002/art.22261. [PubMed] [Cross Ref]
  • Luo W, Wang Y, Hanck T, Stricker R, Reiser G. Jab1, a novel protease-activated receptor-2 (PAR-2)-interacting protein, is involved in PAR-2-induced activation of activator protein-1. J Biol Chem. 2006;281:7927–7936. doi: 10.1074/jbc.M510784200. [PubMed] [Cross Ref]
  • Wang J, Li C, Liu Y, Mei W, Yu S, Liu C, Zhang L, Cao X, Kimberly RP, Grizzle W, Zhang HG. JAB1 determines the response of rheumatoid arthritis synovial fibroblasts to tumor necrosis factor-alpha. Am J Pathol. 2006;169:889–902. doi: 10.2353/ajpath.2006.051161. [PubMed] [Cross Ref]
  • Bakema JE, Hiemstra IH, Bakker J, de Haij S, Kok Y, Adema G, van Egmond M, Coffer PJ, van de Winkel JG, Leusen JH. c-Jun activating binding protein 1 binds to the IgA receptor and modulates protein levels of FcalphaRI and FcRgamma-chain. Eur J Immunol. 2010;40:2035–2040. doi: 10.1002/eji.200939985. [PubMed] [Cross Ref]
  • Yun HM, Baik JH, Kang I, Jin C, Rhim H. Physical interaction of Jab1 with human serotonin 6 G-protein-coupled receptor and their possible roles in cell survival. J Biol Chem. 2010;285:10016–10029. doi: 10.1074/jbc.M109.068759. [PubMed] [Cross Ref]
  • Korbonits M, Chahal HS, Kaltsas G, Jordan S, Urmanova Y, Khalimova Z, Harris PE, Farrell WE, Claret FX, Grossman AB. Expression of phosphorylated p27(Kip1) protein and Jun activation domain-binding protein 1 in human pituitary tumors. J Clin Endocrinol Metab. 2002;87:2635–2643. doi: 10.1210/jc.87.6.2635. [PubMed] [Cross Ref]
  • Fukumoto AIN, Sho M, Tomoda K, Kanehiro H, Hisanaga M, Tsurui Y, Tsutsumi M, Kato JY, Nakajima Y. Prognostic significance of localized p27Kip1 and potential role of Jab1/CSN5 in pancreatic cancer. Oncol Rep. 2004;11:277–284. [PubMed]
  • Harada K, Kawashima Y, Yoshida H, Sato M. High expression of Jun activation domain-binding protein 1 (Jab1) is a strong prognostic marker in oral squamous cell carcinoma patients treated by UFT in combination with radiation. Anticancer Res. 2006;26:1615–1619. [PubMed]
  • Shintani S LC, Mihara M, Hino S, Nakashiro K, Hamakawa H. Skp2 and Jab1 expression are associated with inverse expression of p27(KIP1) and poor prognosis in oral squamous cell carcinomas. Oncology. 2003;65:355–362. doi: 10.1159/000074649. [PubMed] [Cross Ref]
  • Sui L, Dong Y, Ohno M, Watanabe Y, Sugimoto K, Tai Y, Tokuda M. Jab1 expression is associated with inverse expression of p27(kip1) and poor prognosis in epithelial overian tumors. Clin Cancer Res. 2001;7:4130–4135. [PubMed]
  • Wang Y, Cheng C, Ji Y, Zhao Y, Zou L, Shen A. Expression of Jun activation domain-binding protein 1 and Ser10 phosphorylated p27 protein in human epithelial ovarian carcinoma. J Cancer Res Clin Oncol. 2009;135:951–959. doi: 10.1007/s00432-008-0531-y. [PubMed] [Cross Ref]
  • Shen L, Tsuchida R, Miyauchi J, Saeki M, Honna T, Tsunematsu Y, Kato J, Mizutani S. Differentiation-associated expression and intracellular localization of cyclin-dependent kinase inhibitor p27KIP1 and c-Jun co-activator JAB1 in neuroblastoma. Int J Oncol. 2000;17:749–754. [PubMed]
  • Tsuchida R, Miyauchi J, Shen L, Takagi M, Tsunematsu Y, Saeki M, Honna T, Yamada S, Teraoka H, Kato JY, Mizutani S. Expression of cyclin-dependent kinase inhibitor p27/Kip1 and AP-1 coactivator p38/Jab1 correlates with differentiation of embryonal rhabdomyosarcoma. Jpn J Cancer Res. 2002;93:1000–1006. [PubMed]
  • Hashimoto N, Yachida S, Okano K, Wakabayashi H, Imaida K, Kurokohchi K, Masaki T, Kinoshita H, Tominaga M, Ajiki T, Ku Y, Okabayashi T, Hanazaki K, Hiroi M, Izumi S, Mano S, Okada S, Karasawa Y, Maeba T, Suzuki Y. Immunohistochemically detected expression of p27(Kip1) and Skp2 predicts survival in patients with intrahepatic cholangiocarcinomas. Ann Surg Oncol. 2009;16:395–403. doi: 10.1245/s10434-008-0236-0. [PubMed] [Cross Ref]
  • Dong Y, Sui L, Watanabe Y, Yamaguchi F, Hatano N, Tokuda M. Prognostic significance of Jab1 expression in laryngeal squamous cell carcinomas. Clin Cancer Res. 2005;11:259–266. doi: 10.1158/1078-0432.CCR-04-1079. [PubMed] [Cross Ref]
  • Wang F, Wang Y, Yu X, Yang D, Wang Z, Lu C, Yuan Z, Xiao M, Shen A. Significance of Jab1 expression in human esophageal squamous cell carcinoma. J Clin Gastroenterol. 2009;43:520–526. doi: 10.1097/MCG.0b013e3181919245. [PubMed] [Cross Ref]
  • Ivan D, Diwan AH, Esteva FJ, Prieto VG. Expression of cell cycle inhibitor p27Kip1 and its inactivator Jab1 in melanocytic lesions. Mod Pathol. 2004;17:811–818. doi: 10.1038/modpathol.3800123. [PubMed] [Cross Ref]
  • Rassidakis GZ, Claret FX, Lai R, Zhang Q, Sarris AH, McDonnell TJ, Medeiros LJ. Expression of p27(Kip1) and c-Jun activation binding protein 1 are inversely correlated in systemic anaplastic large cell lymphoma. Clin Cancer Res. 2003;9:1121–1128. [PubMed]
  • Wang Y, Fei M, Cheng C, Zhang D, Lu J, He S, Zhao Y, Shen A. Jun activation domain-binding protein 1 negatively regulate p27 kip1 in non-Hodgkin's lymphomas. Cancer Biol Ther. 2008;7:460–467. doi: 10.4161/cbt.7.3.5456. [PubMed] [Cross Ref]
  • Ito Y, Yoshida H, Matsuzuka F, Matsuura N, Nakamura Y, Nakamine H, Kakudo K, Kuma K, Miyauchi A. Jun activation domain-binding protein 1 expression in malignant lymphoma of the thyroid: its linkage to degree of malignancy and p27 expression. Anticancer Res. 2003;23:4121–4125. [PubMed]
  • Ito Y, Yoshida H, Nakamura Y, Tomoda C, Uruno T, Takamura Y, Miya A, Kobayashi K, Matsuzuka F, Kuma K, Kakudo K, Miyauchi A. Expression of Jun activation domain-binding protein 1 and p27 (Kip1) in thyroid medullary carcinoma. Pathology. 2005;37:216–219. doi: 10.1080/00313020500098959. [PubMed] [Cross Ref]
  • Ahn J, Hong SA, Lee SE, Kim J, Oh YS, Park SJ, Chung YJ. Cytoplasmic localization of Jab1 and p27 Kip1 might be associated with invasiveness of papillary thyroid carcinoma. Endocr J. 2009;56:707–713. doi: 10.1507/endocrj.K08E-372. [PubMed] [Cross Ref]
  • Osoegawa A, Yoshino I, Kometani T, Yamaguchi M, Kameyama T, Yohena T, Maehara Y. Overexpression of Jun activation domain-binding protein 1 in nonsmall cell lung cancer and its significance in p27 expression and clinical features. Cancer. 2006;107:154–161. doi: 10.1002/cncr.21961. [PubMed] [Cross Ref]
  • Goto A, Niki T, Moriyama S, Funata N, Moriyama H, Nishimura Y, Tsuchida R, Kato JY, Fukayama M. Immunohistochemical study of Skp2 and Jab1, two key molecules in the degradation of P27, in lung adenocarcinoma. Pathol Int. 2004;54:675–681. doi: 10.1111/j.1440-1827.2004.01679.x. [PubMed] [Cross Ref]
Articles from Cell Division are provided here courtesy of
BioMed Central